Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study Dahiya, S., Hirayama, A. V., Schuster, S. J., Reguera Ortega, J., Morschhauser, F., Garcia-Sancho, A., Kuruvilla, J., Izutsu, K., Maria Barbui, A., Borchmann, P., Mielke, S., Cartron, G., Ghesquieres, H., Goto, H., Varadarajan, I., Kamdar, M., Isufi, I., Farazi, T., Kao, G., Vedal, M., Bhatnagar, R., Nishii, R., Papuga, J., Lia Palomba, M. CIG MEDIA GROUP, LP. 2024: S462-S463View details for Web of Science ID 001315579604131